GlassScriptPhysician profile
Danielle Elizabeth Elbert
NPI 1336768357
$7,996.14
in general payments reported to CMS, 2019-2025
19 companies · $2,493 in 2025
The $2,493 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,066 · 2023: $1,936 · 2024: $2,501 · 2025: $2,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,291 · Education: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,291.22 |
| Education | $638.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,656.48 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $718.82 | 2022-2025 | |
| Janssen Biotech, INC. | $706.01 | 2022-2025 | Tremfya |
| Ucb, INC. | $648.88 | 2023-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $641.82 | 2022-2025 | Ilumya |
| Leo Pharma INC. | $603.70 | 2022-2025 | Adbry, Anzupgo |
| Amgen INC. | $594.66 | 2022-2025 | Otezla, Otezla |
| Abbvie INC. | $483.91 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $355.23 | 2022-2025 | |
| Lilly USA, LLC | $323.32 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $290.95 | 2022-2025 | |
| Incyte Corporation | $272.28 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $193.46 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $137.31 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $106.10 | 2024-2025 | Nemluvio |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $98.61 | 2022-2025 | Seysara, Klisyri |
| Organon LLC | $81.44 | 2025 | Vtama, Hadlima |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Elbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.